Federal Circuit Scrutinizes Purdue Pharma’s Patents on Abuse-Deterrent OxyContin

An attorney for Purdue Pharma faced challenges at the Federal Circuit as he defended the patents for the company’s abuse-deterrent formulation of OxyContin. During the proceedings, the attorney argued that the patents were not obvious despite contentions from opposing parties, emphasizing that rival companies had the chance to develop similar solutions but failed to do so. This highlights the ongoing debate about whether profits from this particular OxyContin product are genuinely derived from its intellectual property. For further details, the full legal analysis can be accessed here.